Muzzey Dale 4

What Happened

• Dale Muzzey, Chief Scientific Officer of Myriad Genetics (MYGN), was awarded 23,697 performance-based restricted stock units (PSUs) on February 2, 2026. The units were acquired at $0.00 (a compensation grant), with a total reported acquisition value of $0. Each PSU represents a contingent right to one share and will vest on March 15, 2026.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 3, 2026 (reporting period 2026-02-02).
• Transaction type/code: Award/Grant (A); Price reported: $0.00; Shares involved: 23,697 PSUs.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: These are PSUs initially granted March 15, 2023; the Compensation and Human Capital Committee determined the final award amount on February 2, 2026 based on pre-determined performance metrics.
• No 10b5-1 plan, tax-withholding, or sale noted in the filing.

Context

• This was a performance-based equity award (compensation), not an open-market purchase or sale. Awards are common for executives and reflect compensation tied to prior performance metrics; they do not by themselves indicate insider buying or selling intent. The PSUs convert to shares upon vesting (March 15, 2026) if the performance conditions remain satisfied.